诺舒阻抗控制子宫内膜切除系统(Novasure)治疗月经过多60例临床分析

Clinical Analysis of Nova Sure Impedance Control Endometrial Ablationl System in Treatment of Abnormal Uterine Bleeding IN 60 Cases

目的:总结诺舒(Nova Sure)阻抗控制子宫内膜去除系统治疗异常子宫出血的有效性、安全性。方法:2014年6月~12月,采用诺舒治疗异常子宫出血60例,分别在门诊于术后1、3、6个月随访,观察其疗效和并发症。结果:平均操作时间(103±14)秒,术后1、3和6个月的有效率均为100%,闭经率分别为80.0%(48/60)、80.0%(48/60)和70.0%(42/60)。60例患者术前血红蛋白(88.0±13.9)g·L^(-1),术后6个月血红蛋白升至(94.2±12.5)g·L^(-1),手术前后比较,差异有统计学意义(t=-2.855,P=0.004)。在30例有内科合并症的患者中,术前血红蛋白(73.2±13.6)g·L^(-1),术后6个月血红蛋白升至(99.6±18.3)g·L^(-1),手术前后比较,差异有统计学意义(t=-2.575,P=0.001),提示诺舒术后血红蛋白明显上升,贫血明显改善。结论:Nova Sure是一项安全、简便、有效的手术,并发症发生率低,可适用合并严重内科疾病的患者,操作简便、机体损伤小、适用范围广。

Objective： To summarize the efficacy and safety of NovaS ure impedance control endometrial ablationl system in the treatment of abnormal uterine bleeding. Methods： 60 cases of abnormal uterine bleeding were treated by NovaS ure from June to December,2014. Follow-up was performed in the outpatient in 1,3,6 months postoperatively to evaluate its efficacy and complications. Results： The average operating time was（ 103 ± 14） seconds; the effectiveness was 100%;the amenorrhoea rates were 80. 0%（ 24 /30）,80. 0%（ 24 /30） and 70. 0%（ 21 /30） for 1,3 and 6 month respectively.Hemoglobin of 6 months after operation was（ 94. 2 ± 12. 5） g·L-1 and the preoperative Hemoglobin was（ 88. 0 ＋ 13. 9）g·L-1. The difference was statistically significant（ paired t test,t = 2. 855,P = 0. 004）. In 30 cases of patients with medical complications,postoperative hemoglobin rose significantly,（ 73. 2 ＋ 13. 6） g · L-1 for 6 months postoperative versus（ 99. 6 ＋ 18. 3） g·L-1,preoperatively,（ paired t test,t = 2. 575,P = 0. 001）. It indicated that postoperative hemoglobin increased significantly and anemia had been improved after NovaS ure percodure. Conclusion： NovaS ure is a safe,simple and effective percodure with low complication rates. It is minimally invasive,and easy o handle,thus deserves a wide range of clinical application.